AT
REGN icon

American Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

American Trust’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-779
Closed -$494K – 308
2025
Q1 		$494K Buy
779
+80
+11% +$55K 0.12% 91
2024
Q4 		$498K Buy
699
+128
+22% +$107K 0.04% 170
2024
Q3 		$600K Buy
+571
New +$635K 0.05% 126

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

American Trust's REGN Position: Q2 2025 in Review

American Trust sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 779 shares — an estimated $494K sold.

American Trust first reported a position in REGN in Q3 2024 and held it in 3 quarters. The position peaked at $600K in Q3 2024. 1,203 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • American Trust reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • American Trust sold 779 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $494K.
  • American Trust first reported a position in Regeneron Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • American Trust's Regeneron Pharmaceuticals position peaked at $600K in Q3 2024.
  • 1,203 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on American Trust's 13F filing for Q2 2025, filed 3 Sep 2025.